Business UpdateMay 29, 2026, 04:03 PM
Arvinas to Present at Jefferies Global Healthcare Conference
AI Summary
Arvinas, Inc. announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, at 9:55 a.m. ET. A live audio webcast of the presentation will be accessible via the company's website. Arvinas is a clinical-stage biotechnology company pioneering protein degradation therapies, including the FDA-approved PROTAC, VEPPANU, developed with Pfizer Inc., and several other investigational drugs in clinical development.
Key Highlights
- Arvinas management to participate in a fireside chat at the Jefferies Global Healthcare Conference.
- Presentation scheduled for Wednesday, June 3 at 9:55 a.m. ET.
- A live audio webcast will be available on the company's website.
- Arvinas is a clinical-stage biotechnology company focused on targeted protein degradation.
- Developed VEPPANU, the first-and-only FDA-approved PROTAC, with Pfizer Inc.
- VEPPANU is for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
- Company is progressing multiple investigational drugs through clinical development programs.
Price Impact
More from ARVN